Belvedere Trading’s Privia Health PRVA Stock Holding History

Belvedere Trading’s Portfolio PRVA Stock Details PRVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100	Closed	-$3K	–	375
2022 Q2	$3K	Buy	+100	New	+$2.54K	﹤0.01%	346

Other funds holding PRVA

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Belvedere Trading's PRVA Position: Q2 2022 in Review

Belvedere Trading sold out of Privia Health (PRVA) in Q2 2022, closing a stake of 10,911 shares — an estimated $277K sold.

Belvedere Trading first reported a position in PRVA in Q1 2022 and held it in 1 quarter. The position peaked at $308K in Q1 2022. 151 funds tracked by Wall St. Rank hold PRVA as of Q2 2022.

Belvedere Trading reported no remaining Privia Health position as of Q2 2022 after selling out during the quarter.
Belvedere Trading sold 10,911 Privia Health shares in Q2 2022, an estimated $277K.
Belvedere Trading first reported a position in Privia Health in Q1 2022 and held it in 1 quarter.
Belvedere Trading's Privia Health position peaked at $308K in Q1 2022.
151 funds tracked by Wall St. Rank held Privia Health as of Q2 2022.

Based on Belvedere Trading's 13F filing for Q2 2022, filed 21 Jul 2022.